Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
Broadly neutralising antibodies may be partners for long-acting antiretrovirals
HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind
Once-weekly antiretrovirals on the horizon
If one antibody won’t work, how about three? Or three in one?
Varying dolutegravir distribution across the body may affect the drug’s ability to suppress the HIV reservoir
People need pathways from PEP to PrEP – and back again
Sexually transmitted infections in San Francisco have fallen since doxyPEP roll-out
Full analysis of French STI study dashes hopes for a gonorrhoea vaccine
